In vivo antigen stability affects DNA vaccine immunogenicity

Journal of Immunology

Volumn 179, Issue 4, 2007, Pages 2126-2133

  Bins, Adriaan D ^a   Wolkers, Monika C ^a,b   Van Den Boom, Marly D ^a   Haanen, John B A G ^a   Schumacher, Ton N M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA VACCINE; TUMOR ANTIGEN; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; GENETIC ENGINEERING; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; VACCINATION; ANIMAL; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGY; MOUSE MUTANT;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; GENETIC ENGINEERING; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; VACCINES, DNA; VIRAL VACCINES;

EID: 34848867527     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.4.2126     Document Type: Article

References (44)

1. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13: 114-119.
2. Rock, K. L., and L. Shen. 2005. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207: 166-183.
3. Bevan, M. J. 1976. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J. Immunol. 117: 2233-2238.
4. Sant, A. J. 1994. Endogenous antigen presentation by MHC class II molecules. Immunol. Res. 13: 253-267.
5. Townsend, A. R., F. M. Gotch, and J. Davey. 1985. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42: 457-467.
6. Whitton, J. L., and M. B. Oldstone. 1989. Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J. Exp. Med. 170: 1033-1038.
7. + CTL following exposure to vaccinia virus via different routes. J. Immunol. 169: 4222-4229.
8. Tillman, B. W., T. D. de Gruijl, S. A. Luykx-de Bakker, R. J. Scheper, H. M. Pinedo, T. J. Curiel, W. R. Gerritsen, and D. T. Curiel. 1999. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162: 6378-6383.
9. + T cell responses in gene gun DNA immunization. J. Immunol. 167: 5549-5557.
10. Doe, B., M. Selby, S. Barnett, J. Baenziger, and C. M. Walker. 1996. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc. Natl. Acad. Sci. USA 93: 8578-8583.
11. Corr, M., A. von Damm, D. J. Lee, and H. Tighe. 1999. In vivo priming by DNA injection occurs predominantly by antigen transfer. J. Immunol. 163: 4721-4727.
12. Basta, S., R. Stoessel, M. Basler, M. van den Broek, and M. Groettrup. 2005. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J. Immunol. 175: 796-805.
13. + T cell cross-priming via transfer of proteasome substrates. Science 304: 1318-1321.
14. Shen, L., and K. L. Rock. 2004. Cellular protein is the source of cross-priming antigen in vivo. Proc. Natl. Acad. Sci. USA 101: 3035-3040.
15. Wolkers, M. C., N. Brouwenstijn, A. H. Bakker, M. Toebes, and T. N. Schumacher. 2004. Antigen bias in T cell cross-priming. Science 304: 1314-1317.
16. + T cells. Nat. Immunol. 6: 593-599.
17. Blachere, N. E., R. B. Darnell, and M. L. Albert. 2005. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol. 3: e185.
18. Serna, A., M. C. Ramirez, A. Soukhanova, and L. J. Sigal. 2003. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells. J. Immunol. 171: 5668-5672.
19. Neijssen, J., C. Herberts, J. W. Drijfhout, E. Reits, L. Janssen, and J. Neefjes. 2005. Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434: 83-88.
20. + T cells in major histocompatibility complex class II-deficient mice. Science 253: 1417-1420.
21. Mombaerts, P., J. Arnoldi, F. Russ, S. Tonegawa, and S. H. Kaufmann. 1993. Different roles of αβ and γδ T cells in immunity against an intracellular bacterial pathogen. Nature 365: 53-56.
22. Mamalaki, C., J. Elliott, T. Norton, N. Yannoutsos, A. R. Townsend, P. Chandler, E. Simpson, and D. Kioussis. 1993. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 3: 159-174.
23. Bins, A. D., A. Jorritsma, M. C. Wolkers, C. F. Hung, T. C. Wu, T. N. Schumacher, and J. B. Haanen. 2005. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 11: 899-904.
24. Lyko, F., B. Martoglio, B. Jungnickel, T. A. Rapoport, and B. Dobberstein. 1995. Signal sequence processing in rough microsomes. J. Biol. Chem. 270: 19873-19878.
25. Reits, E., J. Neijssen, C. Herberts, W. Benckhuijsen, L. Janssen, J. W. Drijfhout, and J. Neefjes. 2004. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20: 495-506.
26. Bachmair, A., D. Finley, and A. Varshavsky. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234: 179-186.
27. Tasaki, T., L. C. Mulder, A. Iwamatsu, M. J. Lee, I. V. Davydov, A. Varshavsky, M. Muesing, and Y. T. Kwon. 2005. A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol. Cell. Biol. 25: 7120-7136.
28. Donnelly, J. J., B. Wahren, and M. A. Liu. 2005. DNA vaccines: progress and challenges. J. Immunol. 175: 633-639.
29. Heath, W. R., G. T. Belz, G. M. Behrens, C. M. Smith, S. P. Forehan, I. A. Parish, G. M. Davey, N. S. Wilson, F. R. Carbone, and J. A. Villadangos. 2004. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199: 9-26.
30. Maecker, H. T., D. T. Umetsu, R. H. DeKruyff, and S. Levy. 1998. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J. Immunol. 161: 6532-6536.
31. Levy, F., N. Johnsson, T. Rumenapf, and A. Varshavsky. 1996. Using ubiquitin to follow the metabolic fate of a protein. Proc. Natl. Acad. Sci. USA 93: 4907-4912.
32. Smahel, M., P. Sima, V. Ludvikova, and V. Vonka. 2001. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238.
33. Burgers, W. A., J. H. van Harmelen, E. Shephard, C. Adams, T. Mgwebi, W. Bourn, T. Hanke, A. L. Williamson, and C. Williamson. 2006. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 sub-type C DNA vaccine for clinical trial. J. Gen. Virol. 87: 399-410.
34. Locher, C. P., N. W. Soong, R. G. Whalen, and J. Punnonen. 2004. Development of novel vaccines using DNA shuffling and screening strategies. Curr. Opin. Mol. Ther. 6: 34-39.
35. + T-cell epitopes. J. Virol. 80: 4717-4728.
36. Delamarre, L., R. Couture, I. Mellman, and E. S. Trombetta. 2006. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 203: 2049-2055.
37. Falk, K., O. Rotzschke, and H. G. Rammensee. 1990. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348: 248-251.
38. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10: 1240-1244.
39. Xin, K. Q., N. Jounai, K. Someya, K. Honma, H. Mizuguchi, S. Naganawa, K. Kitamura, T. Hayakawa, S. Saha, F. Takeshita, et al. 2005. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther. 12: 1769-1777.
40. Nkolola, J. P., E. G. Wee, E. J. Im, C. P. Jewell, N. Chen, X. N. Xu, A. J. McMichael, and T. Hanke. 2004. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 11: 1068-1080.
41. Rodriguez, M. S., J. M. Desterro, S. Lain, D. P. Lane, and R. T. Hay. 2000. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome- mediated degradation. Mol. Cell. Biol. 20: 8458-8467.
42. Khamsri, B., M. Fujita, K. Kamada, A. Piroozmand, T. Yamashita, T. Uchiyama, and A. Adachi. 2006. Effects of lysine to arginine mutations in HIV-1 Vif on its expression and viral infectivity. Int. J. Mol. Med. 18: 679-683.
43. Rivera, V. M., X. Wang, S. Wardwell, N. L. Courage, A. Volchuk, T. Keenan, D. A. Holt, M. Gilman, L. Orci, F. Cerasoli, Jr., et al. 2000. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum. Science 287: 826-830.
44. Banaszynski, L. A., L. C. Chen, L. A. Maynard-Smith, A. G. Ooi, and T. J. Wandless. 2006. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126: 995-1004.